ANAPTYSBIO, INC (ANAB)
Data as of , from SEC Form 4 filings.
See up to 3 months of ANAB. The 7-day demo opens the 1M and 3M ranges and puts ANAB on your watchlist.
Start 7-day demoLatest ANAB insider trades
About ANAPTYSBIO, INC (ANAB)
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
- SAN DIEGO, CA
- 104
- 2017
- XNAS
ANAB Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 5,000 | $249K |
| Grant or award | 2 | 70,001 | |
| Option exercise | 4 | 12,600 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ANAB insider transactions (Form 4)
14343 Form 4 filings on record, the earliest from Dec 3, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Hollings Renton - Director | Option exercise | Common Stock | 5,000 | $18.03 | $90K | |
| Hollings Renton - Director | Open-market sale | Common Stock | 5,000 | $49.87 footnote F2 | $249K | |
| Hollings Renton - Director | Option exercise | Common Stock | 5,000 | $0.00 | - | |
| ||||||
| John A. Orwin - Director | Option exercise | Common Stock | 1,300 | $0.00 footnote F1 | - | |
| John A. Orwin - Director | Option exercise | Restricted Stock Unit | 1,300 | $0.00 | - | |
| ||||||
 Paul F. Lizzul - Officer | Grant or award | Performance Stock Units | 16,667 | $0.00 | - | |
| Daniel Faga - Officer | Grant or award | Performance Stock Units | 53,334 | $0.00 | - | |
| John P. Schmid | Option exercise | Restricted Stock Unit | 6,030 | $0.00 | - | |
| John P. Schmid | Option exercise | Common Stock | 6,030 | $0.00 footnote F1 | - | |
| ||||||
| Hollings Renton | Option exercise | Common Stock | 6,030 | $0.00 footnote F1 | - | |
| Hollings Renton | Option exercise | Restricted Stock Unit | 6,030 | $0.00 | - | |
| ||||||
| John A. Orwin | Option exercise | Restricted Stock Unit | 6,030 | $0.00 | - | |
| John A. Orwin | Option exercise | Common Stock | 6,030 | $0.00 footnote F1 | - | |
| ||||||
| Owen Hughes | Grant or award | Restricted Stock Units | 11,250 | $0.00 | - | |
 Christopher M. Murphy - Officer | Grant or award | Restricted Stock Units | 25,765 | $0.00 | - | |
 Susannah Gray | Grant or award | Restricted Stock Unit | 11,250 | $0.00 | - | |
| Daniel Faga - Officer | Derivative | Employee Stock Option (right to buy) | 11,000 | $0.00 | - | |
| John A. Orwin | Derivative | Stock Option (right to buy) | 3,311 | $0.00 | - | |
| John A. Orwin | Grant or award | Stock Option (right to buy) | 3,311 | $0.00 | - | |
| John A. Orwin | Derivative | Stock Option (right to buy) | 10,600 | $0.00 | - | |
| John A. Orwin | Grant or award | Stock Option (right to buy) | 10,600 | $0.00 | - | |
| John A. Orwin | Derivative | Stock Option (right to buy) | 16,510 | $0.00 | - | |
| John A. Orwin | Derivative | Stock Option (right to buy) | 16,510 | $0.00 | - | |
| John A. Orwin | Grant or award | Stock Option (right to buy) | 16,510 | $0.00 | - | |
| John A. Orwin | Grant or award | Stock Option (right to buy) | 16,510 | $0.00 | - | |
| John A. Orwin | Derivative | Stock Option (right to buy) | 8,250 | $0.00 | - | |
| John A. Orwin | Grant or award | Stock Option (right to buy) | 8,250 | $0.00 | - | |
| John P. Schmid | Derivative | Stock Option (right to buy) | 15,000 | $0.00 | - | |
| John P. Schmid | Grant or award | Stock Option (right to buy) | 15,000 | $0.00 | - | |
| John P. Schmid | Derivative | Stock Option (right to buy) | 6,000 | $0.00 | - | |
| John P. Schmid | Derivative | Stock Option (right to buy) | 6,000 | $0.00 | - | |
| John P. Schmid | Grant or award | Stock Option (right to buy) | 6,000 | $0.00 | - | |
| John P. Schmid | Grant or award | Stock Option (right to buy) | 6,000 | $0.00 | - | |
| John P. Schmid | Derivative | Stock Option (right to buy) | 11,000 | $0.00 | - | |
| John P. Schmid | Derivative | Stock Option (right to buy) | 11,000 | $0.00 | - | |
| John P. Schmid | Grant or award | Stock Option (right to buy) | 11,000 | $0.00 | - | |
| John P. Schmid | Grant or award | Stock Option (right to buy) | 11,000 | $0.00 | - | |
| John P. Schmid | Derivative | Stock Option (right to buy) | 9,200 | $0.00 | - | |
| John P. Schmid | Grant or award | Stock Option (right to buy) | 9,200 | $0.00 | - | |
| John P. Schmid | Derivative | Stock Option (right to buy) | 10,600 | $0.00 | - | |
| John P. Schmid | Grant or award | Stock Option (right to buy) | 10,600 | $0.00 | - | |
| John P. Schmid | Derivative | Stock Option (right to buy) | 16,510 | $0.00 | - | |
| John P. Schmid | Derivative | Stock Option (right to buy) | 16,510 | $0.00 | - | |
| John P. Schmid | Grant or award | Stock Option (right to buy) | 16,510 | $0.00 | - | |
| John P. Schmid | Grant or award | Stock Option (right to buy) | 16,510 | $0.00 | - | |
| John P. Schmid | Derivative | Stock Option (right to buy) | 5,500 | $0.00 | - | |
| John P. Schmid | Grant or award | Stock Option (right to buy) | 5,500 | $0.00 | - | |
| Hollings Renton | Derivative | Stock Option (right to buy) | 15,000 | $0.00 | - | |
| Hollings Renton | Grant or award | Stock Option (right to buy) | 15,000 | $0.00 | - | |
| Hollings Renton | Derivative | Stock Option (right to buy) | 6,000 | $0.00 | - | |
| Hollings Renton | Derivative | Stock Option (right to buy) | 6,000 | $0.00 | - | |
| Hollings Renton | Grant or award | Stock Option (right to buy) | 6,000 | $0.00 | - | |
| Hollings Renton | Grant or award | Stock Option (right to buy) | 6,000 | $0.00 | - | |
| Hollings Renton | Derivative | Stock Option (right to buy) | 11,000 | $0.00 | - | |
| Hollings Renton | Derivative | Stock Option (right to buy) | 11,000 | $0.00 | - | |
| Hollings Renton | Grant or award | Stock Option (right to buy) | 11,000 | $0.00 | - | |
| Hollings Renton | Grant or award | Stock Option (right to buy) | 11,000 | $0.00 | - | |
| Hollings Renton | Derivative | Stock Option (right to buy) | 9,200 | $0.00 | - | |
| Hollings Renton | Grant or award | Stock Option (right to buy) | 9,200 | $0.00 | - | |
| Hollings Renton | Derivative | Stock Option (right to buy) | 10,600 | $0.00 | - | |
| Hollings Renton | Grant or award | Stock Option (right to buy) | 10,600 | $0.00 | - | |
| Hollings Renton | Derivative | Stock Option (right to buy) | 16,510 | $0.00 | - | |
| Hollings Renton | Derivative | Stock Option (right to buy) | 16,510 | $0.00 | - | |
| Hollings Renton | Grant or award | Stock Option (right to buy) | 16,510 | $0.00 | - | |
| Hollings Renton | Grant or award | Stock Option (right to buy) | 16,510 | $0.00 | - | |
| Hollings Renton | Derivative | Stock Option (right to buy) | 5,500 | $0.00 | - | |
| Hollings Renton | Grant or award | Stock Option (right to buy) | 5,500 | $0.00 | - | |
| Daniel Faga - Officer | Derivative | Employee Stock Option (right to buy) | 11,000 | $0.00 | - | |
| Daniel Faga - Officer | Grant or award | Employee Stock Option (right to buy) | 11,000 | $0.00 | - | |
| Daniel Faga - Officer | Derivative | Employee Stock Option (right to buy) | 2,321 | $0.00 | - | |
| Daniel Faga - Officer | Grant or award | Employee Stock Option (right to buy) | 2,321 | $0.00 | - | |
| Daniel Faga - Officer | Derivative | Employee Stock Option (right to buy) | 9,200 | $0.00 | - | |
| Daniel Faga - Officer | Grant or award | Employee Stock Option (right to buy) | 9,200 | $0.00 | - | |
| Daniel Faga - Officer | Derivative | Employee Stock Option (right to buy) | 194,900 | $0.00 | - | |
| Daniel Faga - Officer | Grant or award | Employee Stock Option (right to buy) | 194,900 | $0.00 | - | |
| Daniel Faga - Officer | Derivative | Employee Stock Option (right to buy) | 379,620 | $0.00 | - | |
| Daniel Faga - Officer | Grant or award | Employee Stock Option (right to buy) | 379,620 | $0.00 | - | |
| Daniel Faga - Officer | Derivative | Employee Stock Option (right to buy) | 305,500 | $0.00 | - | |
| Daniel Faga - Officer | Grant or award | Employee Stock Option (right to buy) | 305,500 | $0.00 | - | |
| Daniel Faga - Officer | Derivative | Employee Stock Option (right to buy) | 133,400 | $0.00 | - | |
| Daniel Faga - Officer | Grant or award | Employee Stock Option (right to buy) | 133,400 | $0.00 | - | |
| John P. Schmid | Open-market sale | Common Stock | 12,596 | $55.71 footnote F1 | $702K | |
| John P. Schmid | Open-market sale | Common Stock | 7,527 | $56.70 footnote F2 | $427K | |
| John P. Schmid | Open-market sale | Common Stock | 522 | $57.40 footnote F3 | $30K | |
| ||||||
| Daniel Faga - Officer | Grant or award | Common Stock | 34,300 footnote F1 | - footnote F2 | - | |
| Daniel Faga - Officer | Open-market sale | Common Stock | 510 | $56.61 footnote F4 | $29K | |
| Daniel Faga - Officer | Open-market sale | Common Stock | 2,570 | $57.91 footnote F5 | $149K | |
| Daniel Faga - Officer | Open-market sale | Common Stock | 3,662 | $58.62 footnote F6 | $215K | |
| Daniel Faga - Officer | Open-market sale | Common Stock | 490 | $59.62 footnote F7 | $29K | |
| Daniel Faga - Officer | Open-market sale | Common Stock | 550 | $60.63 footnote F8 | $33K | |
| Daniel Faga - Officer | Open-market sale | Common Stock | 1,012 | $62.15 footnote F9 | $63K | |
| Daniel Faga - Officer | Open-market sale | Common Stock | 2,592 | $63.35 footnote F10 | $164K | |
| Daniel Faga - Officer | Open-market sale | Common Stock | 3,155 | $64.19 footnote F11 | $203K | |
| Daniel Faga - Officer | Open-market sale | Common Stock | 3,038 | $65.20 footnote F12 | $198K | |
| Daniel Faga - Officer | Open-market sale | Common Stock | 100 | $65.99 | $7K | |
| ||||||
 Eric J. Loumeau - Officer | Option exercise | Common Stock | 10,000 | $29.70 | $297K | |
| Eric J. Loumeau - Officer | Open-market sale | Common Stock | 10,000 | $54.00 | $540K | |
| Eric J. Loumeau - Officer | Option exercise | Employee Stock Option (right to buy) | 10,000 | $0.00 | - | |
| Magda Marquet | Option exercise | Common Stock | 11,000 | $26.11 | $287K | |
| Magda Marquet | Open-market sale | Common Stock | 9,290 | $48.12 footnote F1 | $447K | |
| Magda Marquet | Open-market sale | Common Stock | 1,710 | $48.85 footnote F2 | $84K | |
| Magda Marquet | Option exercise | Stock Option (right to buy) | 11,000 | $0.00 | - | |
| ||||||
| Paul F. Lizzul - Officer | Option exercise | Common Stock | 8,525 | - footnote F1 | - | |
| Paul F. Lizzul - Officer | Open-market sale | Common Stock | 3,650 | $44.71 | $163K | |
| Paul F. Lizzul - Officer | Option exercise | Restricted Stock Unit | 8,525 | $0.00 | - | |
| ||||||
 Dennis Mulroy - Officer | Option exercise | Common Stock | 6,700 | - footnote F1 | - | |
| Dennis Mulroy - Officer | Open-market sale | Common Stock | 2,515 | $44.71 | $112K | |
| Dennis Mulroy - Officer | Option exercise | Restricted Stock Unit | 6,700 | $0.00 | - | |
| ||||||
| Eric J. Loumeau - Officer | Option exercise | Common Stock | 5,888 | - footnote F1 | - | |
| Eric J. Loumeau - Officer | Open-market sale | Common Stock | 2,210 | $44.71 | $99K | |
| Eric J. Loumeau - Officer | Option exercise | Restricted Stock Unit | 5,888 | $0.00 | - | |
| ||||||
| Daniel Faga - Officer | Option exercise | Common Stock | 26,838 | - footnote F1 | - | |
| Daniel Faga - Officer | Open-market sale | Common Stock | 14,281 | $44.71 | $639K | |
| Daniel Faga - Officer | Option exercise | Restricted Stock Unit | 26,838 | $0.00 | - | |
| ||||||
| Eric J. Loumeau - Officer | Option exercise | Common Stock | 5,545 | - footnote F1 | - | |
| Eric J. Loumeau - Officer | Open-market sale | Common Stock | 2,017 | $45.11 | $91K | |
| Eric J. Loumeau - Officer | Open-market sale | Common Stock | 5,281 | $45.38 footnote F4 | $240K | |
| Eric J. Loumeau - Officer | Open-market sale | Common Stock | 1,841 | $46.13 footnote F5 | $85K | |
| Eric J. Loumeau - Officer | Open-market sale | Common Stock | 500 | $47.23 | $24K | |
| Eric J. Loumeau - Officer | Option exercise | Restricted Stock Unit | 5,545 | $0.00 | - | |
| Eric J. Loumeau - Officer | Grant or award | Restricted Stock Unit | 17,100 | $0.00 | - | |
| Eric J. Loumeau - Officer | Grant or award | Stock Option (right to buy) | 23,200 | $0.00 | - | |
| ||||||
| Paul F. Lizzul - Officer | Option exercise | Common Stock | 6,145 | - footnote F1 | - | |
| Paul F. Lizzul - Officer | Open-market sale | Common Stock | 2,235 | $45.11 | $101K | |
| Paul F. Lizzul - Officer | Option exercise | Restricted Stock Unit | 6,145 | $0.00 | - | |
| Paul F. Lizzul - Officer | Grant or award | Restricted Stock Unit | 21,400 | $0.00 | - | |
| Paul F. Lizzul - Officer | Grant or award | Stock Option (right to buy) | 29,000 | $0.00 | - | |
| ||||||
| Daniel Faga - Officer | Option exercise | Common Stock | 17,850 | - footnote F1 | - | |
| Daniel Faga - Officer | Open-market sale | Common Stock | 9,202 | $45.11 | $415K | |
| Daniel Faga - Officer | Option exercise | Restricted Stock Unit | 17,850 | $0.00 | - | |
| Daniel Faga - Officer | Grant or award | Restricted Stock Unit | 98,600 | $0.00 | - | |
| Daniel Faga - Officer | Grant or award | Stock Option (right to buy) | 133,400 | $0.00 | - | |
| ||||||
| Dennis Mulroy - Officer | Option exercise | Common Stock | 5,245 | - footnote F1 | - | |
| Dennis Mulroy - Officer | Open-market sale | Common Stock | 1,908 | $45.11 | $86K | |
| Dennis Mulroy - Officer | Grant or award | Stock Option (right to buy) | 29,000 | $0.00 | - | |
| Dennis Mulroy - Officer | Option exercise | Restricted Stock Unit | 5,245 | $0.00 | - | |
| Dennis Mulroy - Officer | Grant or award | Restricted Stock Unit | 21,400 | $0.00 | - | |
| ||||||
| Dennis M. Fenton | Grant or award | Stock Option (right to buy) | 5,500 | $0.00 | - | |
| Dennis M. Fenton | Grant or award | Restricted Stock Unit | 4,000 | $0.00 | - | |
 Rita Jain | Grant or award | Stock Option (right to buy) | 5,500 | $0.00 | - | |
| Rita Jain | Grant or award | Restricted Stock Unit | 4,000 | $0.00 | - | |
| Magda Marquet | Grant or award | Stock Option (right to buy) | 5,500 | $0.00 | - | |
| Magda Marquet | Grant or award | Restricted Stock Unit | 4,000 | $0.00 | - | |
Item 9.01
Item 5.07, 9.01
Item 7.01
Item 1.01
Recent ANAB Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| HOLLINGS C RENTON | Director | 5,000 | $249K | View on EDGAR | |
| - | - | - |
ANAB insider trading FAQ
What is the latest insider trade for ANAB?
ANAPTYSBIO, INC (ANAB) had 4 insider filings in the last 90 days, with the most recent on 2026-10-02. The full record for ANAB runs to 43 Form 4 filings, the earliest from 2024-12-03. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ANAB stock?
No insider purchases of ANAB were filed in the last 90 days.
How many insiders are selling ANAB stock?
1 insider sale of ANAB was filed in the last 90 days, totaling $249K.
Where can I see ANAB SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ANAB Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Hollings Renton view on EDGAR
- - John A. Orwin view on EDGAR
- - Paul F. Lizzul view on EDGAR
- - Daniel Faga view on EDGAR
- - John P. Schmid view on EDGAR
- - Hollings Renton view on EDGAR
- - John A. Orwin view on EDGAR
- - Owen Hughes view on EDGAR
- - Christopher M. Murphy view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where ANAB's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ANAB with a 7-day demo
- ANAB on your watchlist
- Every ANAB Form 4 filing on record
- Up to 3 months of ANAB price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
